Literature DB >> 29940275

Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population.

Qigui Xie1, Zhanlei Chen1, Liang Xia1, Qiufeng Zhao1, Haitao Yu2, Zhuying Yang3.   

Abstract

AIMS: This study was performed to investigate the effect of PD-L1 polymorphisms on the susceptibility and prognosis of hepatocellular carcinoma (HCC) in a Chinese Han population.
METHODS: Four single nucleotide polymorphisms (SNPs) of the PD-L1 gene, including rs2297136 (C > T), rs4143815 (C > G), rs2890658 (A > C) and rs17718883 (C > G) were examined in 225 HCC patients and 200 healthy controls using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method.
RESULTS: Data revealed that the rs2297136 (C > T) SNP TT (p = 0.03) and rs4143815 (C > G) SNP GG genotypes (p < 0.001) were associated with significantly increased risks of HCC. No association was found between rs2890658 (A > C) SNP and HCC risk and this risk was significantly decreased in individuals with the rs17718883 SNP CG + GG genotype (p < 0.001). The rs2297136 (C > T) SNP CC + CT genotypes, the rs4143815 (C > G) CC genotype and the rs2890658 (A > C) AA genotype were associated with increased overall survival compared to their counterpart allelic genotypes (p < 0.001). The rs2890658 (A > C) SNP had no impact on the risk and prognosis of HCC (p > 0.05).
CONCLUSIONS: Our results indicated that three functional polymorphisms (rs2297136, rs4143815 and rs17718883) of the PD-L1 gene were associated with HCC risk and prognosis, suggesting that genetic variants of PD-L1 polymorphisms might be a possible prognostic marker for the prediction of HCC risk and development. Validation by a larger prospective study from a more diverse ethnic population is needed to confirm these findings.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Hepatocellular carcinoma; Prognosis; Programmed death-1 ligand-1; Single nucleotide polymorphisms; Susceptibility

Mesh:

Substances:

Year:  2018        PMID: 29940275     DOI: 10.1016/j.gene.2018.06.069

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  12 in total

1.  PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer.

Authors:  Qing Li; Zhi-Wei Zhou; Jia Lu; Hao Luo; Shu-Nan Wang; Yu Peng; Meng-Sheng Deng; Guan-Bin Song; Jian-Min Wang; Xi Wei; Dong Wang; Kenneth D Westover; Cheng-Xiong Xu
Journal:  Mol Ther       Date:  2021-09-20       Impact factor: 11.454

2.  A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy.

Authors:  Wan Qin; Ben Zhao; Duanrui Wang; Jiamin Liu; Yilu Zhou; Wenjun Zhu; Yongbiao Huang; Hong Qiu; Xianglin Yuan
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

3.  Alpha-Fetoprotein Regulates the Expression of Immune-Related Proteins through the NF-κB (P65) Pathway in Hepatocellular Carcinoma Cells.

Authors:  Qiu-Ting Li; Meng-Jun Qiu; Sheng-Li Yang; Xiefan Fang; Xiao-Xiao He; Meng-Meng Wang; Ya-Nan Li; Zhi-Fan Xiong; Shanshan Huang
Journal:  J Oncol       Date:  2020-07-28       Impact factor: 4.375

4.  Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy.

Authors:  Ming Zhao; Jing Zhang; Siyu Chen; Yuqi Wang; Qing Tian
Journal:  Cancer Manag Res       Date:  2020-08-04       Impact factor: 3.989

Review 5.  Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?

Authors:  D-W Sun; L An; H-Y Huang; X-D Sun; G-Y Lv
Journal:  Clin Transl Oncol       Date:  2020-05-27       Impact factor: 3.405

6.  Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies.

Authors:  Mohammad Hashemi; Shima Karami; Sahel Sarabandi; Abdolkarim Moazeni-Roodi; Andrzej Małecki; Saeid Ghavami; Emilia Wiechec
Journal:  Cancers (Basel)       Date:  2019-08-10       Impact factor: 6.639

Review 7.  Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.

Authors:  Marta Wagner; Monika Jasek; Lidia Karabon
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

8.  Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study.

Authors:  Wenxia Hu; Bin Li; Nan Geng; Xin He; Hui Ge; Ping Wang; Cuimin Ding
Journal:  Int J Gen Med       Date:  2021-06-21

9.  Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.

Authors:  Shima Karami; Hedieh Sattarifard; Mohammad Kiumarsi; Sahel Sarabandi; Mohsen Taheri; Mohammad Hashemi; Gholamreza Bahari; Saeid Ghavami
Journal:  Asian Pac J Cancer Prev       Date:  2020-10-01

10.  Exosomal miR-29b from cancer-associated fibroblasts inhibits the migration and invasion of hepatocellular carcinoma cells.

Authors:  Xingchao Liu; Ping Bie; Hailian Wang; Mei Yang; Yifu Hou; Yunfei Chen
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.